JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer

JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer

Human pancreatic cancer does not respond to immune check point blockade immunotherapy. One key feature of pancreatic cancer is the association between its progression and chronic inflammation. Emerging evidence supports a key role for the JAK-STAT pathway in pancreatic cancer inflammation. We aimed...

Full description

Bibliographic Details
Main Authors:	Chunwan Lu, Asif Talukder, Natasha M. Savage, Nagendra Singh, Kebin Liu
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2017-03-01
Series:	OncoImmunology
Subjects:	cytotoxic t lymphocytes fasl pd-1 pd-l1 ruxolitinib stat1 stat3
Online Access:	http://dx.doi.org/10.1080/2162402X.2017.1291106

Similar Items

Anti-PD1 up-regulates PD-L1 expression and inhibits T-cell lymphoma progression: possible involvement of an IFN-γ-associated JAK-STAT pathway
by: Xue W, et al.
Published: (2019-03-01)

Ruxolitinib Combined with Gemcitabine against Cholangiocarcinoma Growth via the JAK2/STAT1/3/ALDH1A3 Pathway
by: Shin-Yi Chung, et al.
Published: (2021-07-01)

Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK/STAT3/PD-L1 pathway
by: Mingjing Shen, et al.
Published: (2019-04-01)

Dihydropyridine Calcium Channel Blockers Suppress the Transcription of PD-L1 by Inhibiting the Activation of STAT1
by: Xiaohui Pan, et al.
Published: (2021-01-01)

Mediator Kinase Phosphorylation of STAT1 S727 Promotes Growth of Neoplasms With JAK-STAT Activation
by: Ioana I. Nitulescu, et al.
Published: (2017-12-01)

AKR1C1 controls cisplatin-resistance in head and neck squamous cell carcinoma through cross-talk with the STAT1/3 signaling pathway
by: Wei-Min Chang, et al.
Published: (2019-06-01)

Triterpenoid Saponins from Anemone flaccida Suppress Tumor Cell Proliferation by Regulating MAPK, PD1/PDL1, and STAT3 Signaling Pathways and Altering Cancer Metabolism
by: Han L, et al.
Published: (2019-12-01)

SH003 overcomes drug resistance and immune checkpoints by inhibiting JAK-STAT3 signaling in MCF7/ADR cells
by: Jin Mo Ku, et al.
Published: (2021-11-01)

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
by: Angel Garcia-Diaz, et al.
Published: (2017-05-01)

Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer
by: Fan Luo, et al.
Published: (2019-09-01)

JAK Inhibitors and Oxidative Stress Control
by: Amandine Charras, et al.
Published: (2019-12-01)

Prognostic values and clinical implications of programmed cell death-ligand 1 (PD-L1), fork head transcription factor P-1 (FOXP-1) and signal transducer and activator of transcription-3 (STAT-3) expression in diffuse large B-cell lymphoma (DLBCL); an immunohistochemical study
by: Ola A. Harb, et al.
Published: (2019-06-01)

Advances of PD-1/PD-L1 Inhibitors in Tumor Immunotherapy
by: Yong-jun LIU, et al.
Published: (2017-06-01)

Targeting STAT3 Abrogates Tim-3 Upregulation of Adaptive Resistance to PD-1 Blockade on Regulatory T Cells of Melanoma
by: Lili Huang, et al.
Published: (2021-04-01)

Inhibition of STAT3/PD-L1 and Activation of miR193a-5p Are Critically Involved in Apoptotic Effect of Compound K in Prostate Cancer Cells
by: Jae-Hee Lee, et al.
Published: (2021-08-01)

Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects
by: Lu Xu, et al.
Published: (2018-10-01)

The Interplay of Notch Signaling and STAT3 in TLR-Activated Human Primary Monocytes
by: Dagmar Hildebrand, et al.
Published: (2018-07-01)

Inhibition of JAK2/STAT3/SOCS3 signaling attenuates atherosclerosis in rabbit
by: Xilan Yang, et al.
Published: (2020-03-01)

GM-CSF mediates immune evasion via upregulation of PD-L1 expression in extranodal natural killer/T cell lymphoma
by: Qi-xiang Rong, et al.
Published: (2021-05-01)

Silencing of STAT3 via Peptidomimetic LNP-Mediated Systemic Delivery of RNAi Downregulates PD-L1 and Inhibits Melanoma Growth
by: Ehexige Ehexige, et al.
Published: (2020-02-01)

Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma
by: Hyun Jung Kwon, et al.
Published: (2018-11-01)

Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis
by: Camille Keenan, et al.
Published: (2021-02-01)

Plasticity of High-Density Neutrophils in Multiple Myeloma is Associated with Increased Autophagy Via STAT3
by: Fabrizio Puglisi, et al.
Published: (2019-07-01)

PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy
by: Long Jia, et al.
Published: (2018-06-01)

The IL‐27/IL‐27R axis is altered in CD4+ and CD8+ T lymphocytes from multiple sclerosis patients
by: Marie‐Laure Clénet, et al.
Published: (2021-01-01)

STAT3 Activity Promotes Programmed-Death Ligand 1 Expression and Suppresses Immune Responses in Breast Cancer
by: Ioannis Zerdes, et al.
Published: (2019-10-01)

mRNA EXPRESSION OF PD-1, PD-L1, AND IMMUNOTHERAPY IN BLADDER CANCER
by: Muhammad Puteh Mauny, et al.
Published: (2021-07-01)

CHARACTERISTICS OF SIGNALING PATHWAYS MEDIATING A CYTOTOXIC EFFECT OF DENDRITIC CELLS UPON ACTIVATED Т LYMPHOCYTES AND NK CELLS
by: T. V. Tyrinova, et al.
Published: (2014-07-01)

IL-27 Mediates PD-L1 Expression and Release by Human Mesothelioma Cells
by: Grazia Carbotti, et al.
Published: (2021-08-01)

The PD-L1/PD-1 Axis Blocks Neutrophil Cytotoxicity in Cancer
by: Olga Yajuk, et al.
Published: (2021-06-01)

Phosphorylated Forms of STAT1, STAT3 and STAT5 Are Expressed in Proliferating but Not Involuted Infantile Hemangioma
by: Lucy Sulzberger, et al.
Published: (2018-04-01)

A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy
by: Yuanyuan Wang, et al.
Published: (2021-05-01)

Mechanistic Insights of Anti-Immune Evasion by Nobiletin through Regulating miR-197/STAT3/PD-L1 Signaling in Non-Small Cell Lung Cancer (NSCLC) Cells
by: Nipin Sp, et al.
Published: (2021-09-01)

Cancer immunotherapies targeting the PD-1 signaling pathway
by: Yoshiko Iwai, et al.
Published: (2017-04-01)

Interleukin-6 Blocking vs. JAK-STAT Inhibition for Prevention of Lung Injury in Patients with COVID-19
by: Joseph Meletiadis, et al.
Published: (2020-08-01)

A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata
by: Dillon KAL
Published: (2021-06-01)

Interferon-α Up-Regulates the Expression of PD-L1 Molecules on Immune Cells Through STAT3 and p38 Signaling
by: Alexandr V. Bazhin, et al.
Published: (2018-09-01)

The role of exosomal PD-L1 in tumor progression and immunotherapy
by: Feiting Xie, et al.
Published: (2019-10-01)

T cell activation or tolerization: the Yin and Yang of bacterial superantigens
by: Aline eSähr, et al.
Published: (2015-10-01)

Low-Dose Decitabine Inhibits Cytotoxic T Lymphocytes-Mediated Platelet Destruction via Modulating PD-1 Methylation in Immune Thrombocytopenia
by: Panpan Han, et al.
Published: (2021-02-01)